Quarterly Results (Unaudited) - Schedule of Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | 12 Months Ended | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2017 |
Sep. 30, 2017 |
Jun. 30, 2017 |
Mar. 31, 2017 |
Dec. 31, 2016 |
Sep. 30, 2016 |
Jun. 30, 2016 |
Mar. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2017 |
Dec. 31, 2016 |
Dec. 31, 2015 |
||||
Quarterly Financial Information Disclosure [Abstract] | |||||||||||||||
Research and development | $ 1,103 | $ 1,393 | $ 1,255 | $ 2,071 | $ 93,876 | [1] | $ 2,093 | $ 2,368 | $ 3,342 | $ 38,700 | $ 5,822 | $ 101,679 | $ 47,261 | ||
General and administrative | 728 | 717 | (55) | 1,050 | 510 | (199) | 1,836 | 1,992 | 2,440 | 4,140 | 6,765 | ||||
Total costs and expenses | 1,831 | 2,110 | 1,200 | 3,121 | 94,386 | 1,894 | 4,204 | 5,334 | 8,262 | 105,819 | 54,026 | ||||
Operating loss | (1,831) | (2,110) | (1,200) | (3,121) | (94,386) | (1,894) | (4,204) | (5,334) | (8,262) | (105,819) | (53,948) | ||||
Other income (expense), net | (152) | 150 | 198 | 573 | (762) | 13 | 977 | 1,322 | |||||||
Income tax benefit | 6,880 | 29,394 | (6,880) | (29,394) | (15,248) | ||||||||||
Net (loss) income | $ 4,897 | $ (1,960) | $ (1,002) | $ (2,548) | $ (65,754) | $ (1,881) | $ (3,227) | $ (4,012) | $ (613) | $ (74,874) | $ (50,122) | ||||
Basic earnings (loss) per common share | $ 0.20 | $ (0.08) | $ (0.04) | $ (0.11) | $ (3.06) | $ (0.03) | $ (0.14) | $ (0.17) | $ (0.03) | $ (3.18) | $ (2.40) | ||||
Earnings (loss) per common share assuming dilution | $ 0.20 | $ (0.08) | $ (0.04) | $ (0.11) | $ (3.06) | $ (0.03) | $ (0.14) | $ (0.17) | $ (0.03) | $ (3.30) | $ (2.40) | ||||
|
X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|